Entrepreneur Workshop
Fa Liu
CSO, Full-Life Technologies
Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiotherapeutics company with operations in Europe, the United States, and China.
Dr. Liu is the CSO of Full-Life Technologies, which is focusing on targeted alpha therapies. Prior to joining Full-Life, he was the CEO and Co-founder of Focus-X Therapeutics, a Radionuclide-Drug Conjugate company which was recently acquired by Full-Life (2020-2022). Before founding Focus-X, Dr. Liu headed Discovery Chemistry of Novo Nordisk US sites, and Calibrium LLC (acquired by Novo Nordisk) (2014-2020), and served as a Team Leader at the Eli Lilly Peptide Group (2009-2014). Prior to Lilly, Dr. Liu worked at National Cancer Institute (2004-2009). He received his Ph.D. from Shanghai Institute of Organic Chemistry in 2004.